This discrepancy can be attributed to the enrollment of predominantly estrogen receptor-positive patients with a favorable prognosis, along with a high proportion (91.6%) of lymph node-negative individuals, which diminished the risk stratification associated with lymph node metastasis. The gene discussed is ESR1; the disease is metastatic malignant neoplasm in the lymph nodes.